产品中心

LY-2584702 free base

型号:

产品价格:电议      采购度:1609      原产地:美洲

发布时间:2021/7/26 17:04:08      所属地区:上海 上海市

简要描述:

LY-2584702 free base 是一种 ATP 竞争性的选择性 p70S6K 抑制剂,IC50 为 4 nM。LY-2584702 抑制 S6K1 的 IC50 为 2 nM。

产品咨询 服务电话:
021-58955995
分享到:

标签:ly-2584702   

产品详情

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。

LY-2584702 free base

CAS No. : 1082949-67-4

MCE 站:LY-2584702 free base

产品活性:LY-2584702 free base 是一种 ATP 竞争性的选择性 p70S6K 抑制剂,IC50 为 4 nM。LY-2584702 抑制 S6K1IC50 为 2 nM。

研究领域:MAPK/ERK Pathway

作用靶点:Ribosomal S6 Kinase (RSK)

In Vitro: LY-2584702 (LY2584702) inhibits phosphorylation of the S6 ribosomal protein (pS6) in HCT116 colon cancer cells with an IC50 of 0.1-0.24 μM. For pS6 inhibition in cells, the IC50=100 nM. LY-2584702 has some activity against the S6K-related kinases MSK2 and RSK at high concentrations (enzyme assay IC50=58-176 nM). LY-2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose-dependent manner. Proliferation of A549 is significantly inhibited by LY-2584702 (LY2584702) treating over 24 h at 0.1 μM (P<0.05); and the trend of decline is more conspicuous with longer treatment and/or with the increased drug concentration (all P<0.05). Similar results are also observed in SK-MES-1, although the obvious inhibition is led by LY-2584702 at 0.6 μM (P<0.05), much higher than that of A549.

In Vivo: LY-2584702 demonstrates significant single-agent efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models at two dose levels of 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID. LY-2584702 demonstrates statistically significant tumour growth reduction at TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) and TMED90 (10 mg/kg) in the HCT116 colon carcinoma xenograft model. To examine the role of S6K in vivo, EOMA cells expressing shAkt3 are implanted in nu/nu mice, then treated for 14 days with LY-2584702 or Rapamycin. Analysis of tumors removed after 14 days shows that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Loss of Akt3 increases tumor growth as compared with pLKO. LY-2584702 treatment alone does not significantly affect the growth of pLKO tumors. However, LY-2584702 significantly reduces the growth of tumors with shAkt3.

相关产品:PF-4708671  |  Carnosol  |  Pluripotin  |  LJH685  |  Sodium Salicylate  |  LJI308  |  Quercitrin  |  SL 0101-1  |  CKI-7 free base  |  AT7867 dihydrochloride  |  BRD7389  |  Eudesmin  |  SM1-71

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
•   设有专业的实验中心和严格的质控、验证体系;
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
•   产品的生物活性多经各国客户实验验证;
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
•   专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
•   与世界各大制药公司及知名科研机构建立了长期的合作。

1000+ Inhibitors&Agonists 作用于20多条经典信号通路
30+ Screening Libraries 疾病机制研究的高效工具
CCK8 Kit | Cell Counting Kit-8
FDA-Approved 药物筛选库
Inhibitor Cocktails 蛋白酶, 磷酸酶 & 去乙酰化酶
Top Publications Citing Use of MCE
MCE Hotline: 4008203792 | 中国现货 - 全球文献引用 - 高纯度高品质 - 全方位技术支持

更新时间:2024/1/2 10:15:57

留言咨询

  •  
  •  
  •  
  •  
  •  
  •  
  •  
验证码: 点击切换验证码

温馨提示

1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。

相关新闻

相关产品

联系我们

电话:021-58955995
传真:021-53700325
邮箱:sales@medchemexpress.cn
地址:上海上海

版权所有©MedChemExpress, All Right Reseverd ICP备案号: 总访问量:10152152 管理登录 阿仪网 设计制作,未经允许翻录必究

8

阿仪网推荐收藏该企业网站

联系方式

18019480960
18019480960

工作时间

(24小时)